Skip to main content

Advertisement

SpringerLink
Log in

Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the anatomical and functional efficacy of ranibizumab on vascularized pigment epithelial detachment (V-PED) secondary to neovascular age-related macular degeneration (nAMD).

Methods

One hundred and nine patients (116 eyes) were retrospectively selected from medical records of 2097 patients who benefited from intravitreal injection between January 2011 and June 2013 in a tertiary-care University-based Department of Ophthalmology. Inclusion criteria were: nAMD, treatment-naive eyes, presence of V-PED higher than 250 μm, intravitreal ranibizumab with a loading phase, followed by a pro-re-nata regimen, and 1-year follow-up. Baseline characteristics and type of choroidal neovascularization (CNV) were analyzed. PED height, central macular thickness (CMT) and best-corrected visual acuity (BCVA, logMAR) were measured at baseline, months 3, 6 and 12.

Results

CNV was of type 1 in 91 eyes (78.4 %), type 2 in seven (6 %), type 3 in six (5.2 %), and polypoidal choroidal vasculopathy in 12 (10.3 %). Mean CMT at baseline was 572.1 μm and decreased to 396.6 μm (p < 0.0001) at 12 months. Mean height of PED was 458.2 μm at baseline and 306.8 μm (p < 0.0001) at 12 months. Mean BCVA improved from 0.46 at baseline to 0.39 at 12 months (p = 0.013).

Conclusions

Treatment with ranibizumab improved visual and anatomical outcome in nAMD patients with V-PED.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE (2007) Fifteen-year cumulative incidence of age-related macular degeneration. Ophthalmology 114(2):253–262

    Article  PubMed  Google Scholar 

  2. Querques G, Srour M, Massamba N et al (2013) Functional characterization and multimodal imaging of treatment-naïve “quiescent” choroidal neovascularization. Invest Opthalmol Vis Sci 54(10):6886–6892

    Article  Google Scholar 

  3. Zayit-Soudry S, Moroz I, Loewenstein A (2007) Retinal pigment epithelial detachment. Surv Ophthalmol 52(3):227–243

    Article  PubMed  Google Scholar 

  4. Pepple K, Mruthyunjaya P (2011) Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options. Semin Ophthalmol 26(3):198–208

    Article  PubMed  Google Scholar 

  5. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE (1992) Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 230(1):11–19

    Article  CAS  PubMed  Google Scholar 

  6. Poliner LS, Olk RJ, Burgess D, Gordon ME (1986) Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology 93(5):543–551

    Article  CAS  PubMed  Google Scholar 

  7. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444

    Article  CAS  PubMed  Google Scholar 

  8. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431

    Article  CAS  PubMed  Google Scholar 

  9. Iordanous Y, Powell A, Mao A et al (2014) Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration. Can J Ophthalmol 49(4):367–376

    Article  PubMed  Google Scholar 

  10. Suzuki M, Nagai N, Izumi-Nagai K et al (2014) Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol 98(9):1186–1191

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ersoy L, Ristau T, Kirchhof B, Liakopoulos S (2014) Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 252(6):889–897

    Article  CAS  PubMed  Google Scholar 

  12. Giansanti F, Bacherini D, Giacomelli G et al (2014) Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. Eur J Ophthalmol 24(3):402–408

    Article  PubMed  Google Scholar 

  13. Panos GD, Gatzioufas Z, Petropoulos IK, Dardabounis D, Thumann G, Hafezi F (2013) Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. Drug Des Devel Ther 7:565–569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ho AC, Busbee BG, Regillo CD et al (2014) Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121(11):2181–2192

    Article  PubMed  Google Scholar 

  15. Souied EH, Oubraham H, Mimoun G, Cohen SY, Quere S, Derveloy A (2015) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the TWIN study. Retina 35(9):1743–1749

    Article  PubMed  Google Scholar 

  16. Querques G, Azrya S, Martinelli D et al (2010) Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 94(3):292–296

    Article  PubMed  Google Scholar 

  17. Lalwani GA, Lalwani GA, Rosenfeld PJ et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148(1):43.e1–58.e1

    Article  Google Scholar 

  18. Busbee BG, Ho AC et al (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120(5):1046–1056

    Article  PubMed  Google Scholar 

  19. CATT research group, Martin DF, Maquire MG, Ying GS et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Eng J Med 364(20):1897–1908

    Article  Google Scholar 

  20. Gass JD (1984) Pathogenesis of tears of the retinal pigment epithelium. Br J Ophthalmol 68(8):513–519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Schmidt-Erfurth U, Eldem B, Guymer R et al (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5):831–839

    Article  PubMed  Google Scholar 

  22. Arora S, McKibbin M (2011) One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye 25(8):1034–1038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Simader C, Ritter M, Bolz M et al (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121(6):1237–1245

    Article  PubMed  Google Scholar 

  24. Ying G, Huang J, Maguire MG et al (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120(1):122–129

    Article  PubMed  Google Scholar 

  25. Ying G, Kim BJ, Maguire MG et al (2014) Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 132(8):915–921

    Article  PubMed  PubMed Central  Google Scholar 

  26. Schmidt-Erfurth U, Waldstein SM, Deak G, Kundi M, Simader C (2015) Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122(4):822–832

    Article  PubMed  Google Scholar 

  27. Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. Retina 33(5):990–997

    Article  PubMed  Google Scholar 

  28. Varshney N, Jain A, Chan V, Yu L, Sarraf D (2013) Anti-VEGF response in macular hemorrhage and incidence of retinal pigment epithelial tears. Can J Ophthalmol 48(3):210–215

    Article  PubMed  Google Scholar 

  29. Sarraf D, Chan C, Rahimy E, Abraham P (2013) Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy. Retina 33(8):1551–1557

    Article  CAS  PubMed  Google Scholar 

  30. Chiang A, Chang LK, Yu F, Sarraf D (2008) Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 28(9):1265–1269

    Article  PubMed  Google Scholar 

  31. Sarraf D, Reddy S, Chiang A, Yu F, Jain A (2010) A new grading system for retinal pigment epithelial tears. Retina 30(7):1039–1045

    Article  PubMed  Google Scholar 

  32. Sarraf D, Joseph A, Rahimy E (2014) Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 112:142–159

    PubMed  PubMed Central  Google Scholar 

  33. Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW (2016) Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol 166:112–119

    Article  CAS  PubMed  Google Scholar 

  34. Sakai T, Okano K, Kohno H, Tsuneoka H (2016) Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Acta Ophthalmol. doi:10.1111/aos.13130

    PubMed  Google Scholar 

  35. Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I (2015) Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol 160(4):732–738

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 40 Avenue de Verdun, 94000, Creteil, France

    Olivier Chevreaud, Hassiba Oubraham, Salomon Y. Cohen, Rocio Blanco-Garavito, Farah Gherdaoui & Eric H. Souied

  2. Clinical Research Center, Centre Hospitalier Intercommunal, Creteil, France

    Camille Jung

Authors
  1. Olivier Chevreaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hassiba Oubraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salomon Y. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Camille Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rocio Blanco-Garavito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Farah Gherdaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eric H. Souied
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hassiba Oubraham.

Ethics declarations

Funding

No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of retrospective study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chevreaud, O., Oubraham, H., Cohen, S.Y. et al. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results. Graefes Arch Clin Exp Ophthalmol 255, 743–751 (2017). https://doi.org/10.1007/s00417-016-3564-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-016-3564-y

Keywords

Search

Navigation